The EPO issued European Patent Application EP3774885A2 for Merus B.V., a Dutch biotechnology company, covering multivalent antibody constructs for therapeutic applications. The patent specifies antibody formats against multiple targets including infectious disease antigens (C07K 16/12, 16/18), cell surface markers (C07K 16/28), and plasma proteins (C07K 16/36), with primary indication claims for cancer treatment under A61P 35/00.

Pharmaceutical and biotechnology companies developing bispecific or multispecific antibody therapeutics should review this patent to assess freedom-to-operate implications in European markets. The patent provides Merus with exclusivity through designated states including Germany, France, UK, Italy, Spain, and other major European commercial territories. Companies should conduct freedom-to-operate analyses before entering clinical development or commercialization of similar antibody formats in these territories.